10th Microbiome R&D and Business Collaboration Forum: Europe
The Hague, Netherlands
11:50 am – 12:40 pm
Understanding the impact of the microbiota on the gut brain axis is key to exploring prophylactic or therapeutic approaches. The complexity and interindividual diversity of the gut microbiota, the impact of environment, diet, drugs and stresses, make it difficult to manage or manipulate the microbiota. Learnings from animal models, especially humanised rodent models, from 3D brain and gut organoids or advanced co-culture systems, can help understand the complex interactions between the host and his/her microbiota.
New sophisticated diagnostic tools applied in humans allow to not only know “who” is there, but also “what are they doing there”. When applied on a large number of people, healthy and diseased, accumulated data will feed artificial intelligence algorithms, permitting to identify high-risk patients at an early stage, determine imbalances, whether microbiological, immunological, endocrinological or metabolic in nature, and suggest possible prophylactic interventions to mitigate risks.
Abstract based on Chakrabarti et al., Cellular and Molecular Life Sciences (2022) 79:80 ; https://doi.org/10.1007/s00018-021-04060-w
- Prof. Colette Shortt, University of Ulster (UK)
- Dr Bruno Pot, Yakult Europe (NL)
- Dr David Vauzour, University of East Anglia (UK)
- Dr Lesley Hoyles, Nottingham Trent University (UK)
- Dr Elaine Patterson, Novozymes OneHealth (IE)
This event was organised by the Gut-Brain Axis Initiative of ILSI Europe